Judul: Association of microRNA-224 and microRNA-155 expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction

Notes Editorial Office <em@editorialmanager.com>
To: Surya Dharma
Tue, Oct 6, 2020 at 4:24 PM
RESN-D-20-01042R3
Association of microRNA-224-3p and microRNA-155-5p expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction
Surya Dharma, MD, PhD; Iwan Dakota, MD, PhD; Shoma Wijaya, MSc; Elok Ekawati, BSc; Renan Sukmawan, MD, PhD; Bambang Budi Siswanto, MD, PhD, Professor
BMC Research Notes

Dear Dr Dharma,

I am pleased to inform you that your manuscript "Association of microRNA-224-3p and microRNA-155-5p expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction" (RESN-D-20-01042R3) has been accepted for publication in BMC Research Notes.

If any final comments have been submitted from our reviewers or editors, these can be found at the foot of this email for your consideration.

Before publication, our production team will also check the format of your manuscript to ensure that it conforms to the standards of the journal. They will be in touch shortly to request any necessary changes, or to confirm that none are needed.

Articles in this journal may be held for a short period of time prior to publication. If you have any concerns please contact the journal.

Please do not hesitate to contact us if you have any questions regarding your manuscript and I hope that you will consider BMC Research Notes again in the future.

If you wish to co-submit a data note to be published in BMC Research Notes (https://bmcresnotes.biomedcentral.com/about/introducing-data-notes) you can do so by visiting our submission portal http://www.editorialmanager.com/resn/. Data notes support open data (https://www.springernature.com/gp/open-research/open-data) and help authors to comply with funder policies on data sharing. Please note that this additional service is entirely optional.

Best wishes,

Amelia De Salis
BMC Research Notes

BMC Research Notes Editorial Office <em@editorialmanager.com>
To: Surya Dharma
Thu, Sep 3, 2020 at 9:18 PM

RESN-D-20-01042R1
Association of microRNA-224-3p and microRNA-155-5p expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction
Surya Dharma, MD, PhD; Iwan Dakota, MD, PhD; Shoma Wijaya, MSc; Elok Ekawati, BSc; Renan Sukmawan, MD, PhD; Bambang Budi Siswanto, MD, PhD, Professor
BMC Research Notes

Dear Dr Dharma,

Your manuscript "Association of microRNA-224-3p and microRNA-155-5p expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction" (RESN-D-20-01042R1) has been assessed by our reviewers. They have raised a number of points which we believe would improve the manuscript and may allow a revised version to be published in BMC Research Notes.

Their reports, together with any other comments, are below. Please also take a moment to check our website at https://www.editorialmanager.com/resn/ for any additional comments that were saved as attachments.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Research Notes.

Once you have made the necessary corrections, please submit online at the journal's website.

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/resn/. For security reasons, your password will be reset.

Your resubmission must contain the following:
1. Point-by-point response letter
2. Track-changes version of your revised manuscript
3. A clean version of your revised manuscript

The point-by-point letter must provide a detailed response to each reviewer/editorial point and describe the amendments that have been made and where these can be viewed (e.g. Methods section, page 5, line 12). If you disagree with any comments raised, please provide a detailed rebuttal to justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 23 Sep 2020.

Please note, if your manuscript is accepted you will not be able to make any changes to the authors, or order of authors, of your manuscript once the editor has accepted your manuscript for publication. If you wish to make any changes to authorship before you resubmit your revisions, please reply to this email and ask for a 'Request for change in authorship' form which should be completed by all authors (including those to be removed) and returned to this email address. Please ensure that any changes in authorship fulfil the criteria for authorship as outlined in BioMed Central's editorial policies (http://www.biomedcentral.com/about/editorialpolicies#authorship).

Once you have completed and returned the form, your request will be considered and you will be advised whether the requested changes will be allowed.
By resubmitting your manuscript you confirm that all author details on the revised version are correct, that all authors have agreed to authorship and order of authorship for this manuscript and that all authors have the appropriate permissions and rights to the reported data.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorised attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

I look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Tamara Hughes
BMC Research Notes
https://bmcresnotes.biomedcentral.com/

Editor Comments:
Please finds some follow up comments from the reviewers below. Please further address the following points:
1. We noted that you did not discuss any of the short comings that you were not able to address, e.g. (i) drugs especially antiaggregans, anticoagulants, nitrates can affect coronary MVO; (ii) hematologic markers had been demonstrated to be independent markers of MVO, but have not been assessed here; (iii) it is possible that PTX3 was derived from other cells rather the circulating leukocytes where the miR-224 levels were analyzed. Please ensure to add these discussions points and highlight relevant shortcomings and limitations.
2. Not all statistical information was added to the section, e.g. you are stating that you used a Back-wald logistic regression analysis for Table 2. Please update the statistical analysis section accordingly.

Reviewer reports:
Reviewer 2: In the revised submission, the authors provided additional clarifications and better detail their discussion. However, their new C-statistic analyses failed to show a significant discriminative power of miR-224 and miR-155 for MVO, thus reducing the relevance of these miRNAs as possible diagnostic markers. Overall, manuscript is improved in its clarity and the authors better discuss and explain their analyses. Yet, the lack of significance in C-statistics must - at least - be disclosed among the limitation of the study.

Besides this, some minor issues should be also fixed in the manuscript, namely:

1) Pg. 10, ll.45-49: it is unclear how a miRNA could target a SNP? Do the authors refer to a binding site in the 3'UTR which is disrupted by the rs2306519 SNP? Which is the gene involved/affected by this SNP? Is it PTX3? These aspects should be better explained

2) The 95%CI (or other measures of uncertain) should be reported in the manuscript every time that an Odds Ratio or a median/mean difference is stated into the manuscript in the result section (e.g. the median-fold increases in pg. 8).

3) The lack of an independent validation cohort should be disclosed among limitations

4) The authors could consider show the ROC curve for PTX3 among the figures. Moreover, they could consider include a Forest plot depicting the odds ratios derived by the multivariate regression models.

BMC Research Notes Editorial Office <em@editorialmanager.com>
To: Surya Dharma
Thu, Jun 4, 2020 at 9:00 PM
Association of microRNA-224 and microRNA-155 expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction
Surya Dharma, MD, PhD; Iwan Dakota, MD, PhD; Shoma Wijaya, MSc; Elok Ekawati, BSc; Renan Sukmawan, MD, PhD; Bambang Budi Siswanto, MD, PhD, Professor
BMC Research Notes

Dear Dr Dharma,

Thank you for approving the changes and returning your submission entitled 'Association of microRNA-224 and microRNA-155 expressions with plasma long pentraxin 3 concentration and coronary microvascular obstruction following primary angioplasty for acute ST-segment elevation myocardial infarction'.

You will be able to check on the progress of your manuscript during the peer review process by logging on to Editorial Manager as an author.

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/resn/. For security reasons, your password will be reset.

Thank you for submitting your work to BMC Research Notes.

Best wishes,

Editorial Office
BMC Research Notes
https://bmcresnotes.biomedcentral.com/